Major Depression - Cystine/glutamate antiporter

Project Details


Major depression is a frequent mood disorder, often leading to reduced quality of life. In the last half century antidepressant therapy has been dominated by the monoamine hypothesis. Since only 50-60% of depressed patients respond to a first antidepressant treatment, there is room for improvement and necessity for the development of new medication. The recent glutamate hypothesis shows that glutamate is a primary mediator of major depression and thus a potentially interesting target for antidepressant therapy. Very recently, the interest in glial glutamate transporters also increased in the pathophysiology of depression, since they play an important role in the abnormal extrasynaptic glutamine concentration.Research hypothesis:
Effective start/end date1/01/1331/12/16

Flemish discipline codes

  • Neuropsychology
  • Neurosciences
  • Chemical product design and formulation
  • Public health care
  • Drug discovery and development


  • Aminoacids
  • Parkinsons Disease
  • Neuro-Transmitters
  • Neuropharmacology
  • clinical pharmacy
  • Stroke
  • Receptors
  • Rat Models
  • Neurochemistry
  • Pharmacokinetics
  • Microdialysis
  • Drug Research
  • neuroscience
  • Bioanalysis
  • Epilepsy
  • Neurosciences
  • seamless care
  • Monoamines
  • Liquid Chromatography
  • pharmaceutical care
  • Electrochemical Detection